Experimental asthma persists in IL-33 receptor knockout mice because of the emergence of thymic stromal lymphopoietin-driven IL-9 and IL-13 type 2 innate lymphoid cell subpopulations.

J Allergy Clin Immunol

Department of Medicine, Division of Allergy & Immunology, National Jewish Health, Denver, Colo; School of Medicine, University of Colorado Denver, Denver, Colo. Electronic address:

Published: September 2018


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: IL-33 plays an important role in the development of experimental asthma.

Objective: We sought to study the role of the IL-33 receptor suppressor of tumorigenicity 2 (ST2) in the persistence of asthma in a mouse model.

Methods: We studied allergen-induced experimental asthma in ST2 knockout (KO) and wild-type control mice. We measured airway hyperresponsiveness by using flexiVent; inflammatory indices by using ELISA, histology, and real-time PCR; and type 2 innate lymphoid cells (ILC2s) in lung single-cell preparations by using flow cytometry.

Results: Airway hyperresponsiveness was increased in allergen-treated ST2 KO mice and comparable with that in allergen-treated wild-type control mice. Peribronchial and perivascular inflammation and mucus production were largely similar in both groups. Persistence of experimental asthma in ST2 KO mice was associated with an increase in levels of thymic stromal lymphopoietin (TSLP), IL-9, and IL-13, but not IL-5, in bronchoalveolar lavage fluid. Expectedly, ST2 deletion caused a reduction in IL-13 CD4 T cells, forkhead box P3-positive regulatory T cells, and IL-5 ILC2s. Unexpectedly, ST2 deletion led to an overall increase in innate lymphoid cells (CD45linCD25 cells) and IL-13 ILC2s, emergence of a TSLP receptor-positive IL-9 ILC2 population, and an increase in intraepithelial mast cell numbers in the lung. An anti-TSLP antibody abrogated airway hyperresponsiveness, inflammation, and mucus production in allergen-treated ST2 KO mice. It also caused a reduction in innate lymphoid cell, ILC2, and IL-9 and IL-13 ILC2 numbers in the lung.

Conclusions: Genetic deletion of the IL-33 receptor paradoxically increases TSLP production, which stimulates the emergence of IL-9 and IL-13 ILC2s and mast cells and leads to development of chronic experimental asthma. An anti-TSLP antibody abrogates all pathologic features of asthma in this model.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945345PMC
http://dx.doi.org/10.1016/j.jaci.2017.10.020DOI Listing

Publication Analysis

Top Keywords

experimental asthma
16
il-9 il-13
16
innate lymphoid
16
il-33 receptor
12
airway hyperresponsiveness
12
st2 mice
12
thymic stromal
8
type innate
8
lymphoid cell
8
asthma st2
8

Similar Publications

Comparative analysis of biologics' effects on lung function parameters in severe asthma.

Ann Allergy Asthma Immunol

September 2025

Department of Pneumology, University Hospital Saint-Luc, Brussels, Belgium; Pole Pneumology, ENT, and Dermatology - LUNS, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium.

Background: Different biologics available as add-on treatment for severe asthma (SA) showed modest benefits on lung function parameters but head-to-head comparisons are lacking.

Objective: This study aims to compare the effects of four biologics on lung function parameters (including small airways) at 6 and 12 months of treatment in patients with SA.

Methods: An observational multicenter study was conducted on adults patients with SA naïve to biologics treated by benralizumab, dupilumab, mepolizumab and omalizumab with lung function assessment by spirometry and gas dilution method at baseline (T0), after 6 (T6) and 12 months (T12) of treatment.

View Article and Find Full Text PDF

Thymic stromal lymphopoietin as a therapeutic target in patients with chronic rhinosinusitis and nasal polyps.

Clin Exp Immunol

September 2025

Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.

Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disorder of the sinonasal mucosa, predominantly characterized by epithelial dysfunction and chronic heterogeneous mucosal inflammation. CRSwNP and asthma are common comorbidities with overlapping pathophysiology, epithelial impairment and activation of downstream type 2 inflammation. Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine that sits at the top of the immunological cascade and initiates and amplifies type 2-dependent and -independent inflammatory responses.

View Article and Find Full Text PDF

Systematic Literature Review of Real-world Outcomes of Benralizumab in Eosinophilic Granulomatosis with Polyangiitis.

J Allergy Clin Immunol Pract

September 2025

Division of Pulmonary, Critical Care, and Sleep Medicine, National Jewish Health, Denver, Colorado, USA. Electronic address:

Background: Several real-world cohorts and numerous case reports investigating benralizumab outcomes in eosinophilic granulomatosis with polyangiitis have been published. These studies complement the limited clinical trial data available by providing early insights on benralizumab use in a broader, real-world population.

Objective: The objective of this systematic literature review (SLR) was to provide an overview of the real-world outcomes of benralizumab in EGPA.

View Article and Find Full Text PDF

Observational analysis of biological remission as a treatment target for severe asthma: UK severe asthma registry.

J Allergy Clin Immunol Pract

September 2025

Wellcome Wolfson Institute for Experimental Medicine, Queen's University Belfast, UK; Belfast Health and Social Care Trust, Belfast, UK.

Background: The aim of biologic therapies in severe asthma is inhibition of T2 inflammatory pathways.

Objective: We hypothesized that patients who achieve complete suppression of IL-5 & IL4/IL13 pathways with biologic therapy (FeNO <20ppb & blood eosinophil count (BEC) <0.15x10ˆ9, 'biological remission') would have better outcomes than patients with incomplete suppression of T2 biology.

View Article and Find Full Text PDF

Copper oxide nanoparticles (CuONPs) are increasingly used across various industrial applications, raising concerns about their potential toxicity and necessitating comprehensive safety evaluations. In this study, we first evaluated the respiratory toxicity of CuONP exposure in a mouse model of asthma. CuONP exposure alone exacerbated asthma symptoms, as evidenced by increased airway hyperresponsiveness, inflammatory cell infiltration, and elevated cytokine production with increasing thioredoxin-interacting protein (TXNIP) expression.

View Article and Find Full Text PDF